dual gip/glp-1 receptor agonist GLP-1/GIP agonists mechanism of action Machine learning designs new GCGR/GLP-1R
Description
semaglutide was approved for marketing in the United States in September 2017 66
doi:10.3390/ijms19010026 81
Expert Opinion on Drug Metabolism & Toxicology
Efficacy and safety of co-administered once-weekly cagrilintide 24 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Dehydration can affect kidney function
